ArticleCancers2013
Leptin's Pro-Angiogenic Signature in Breast Cancer.
Article in Cancers, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 75 citations in OpenAlex.
- Trial
- Remodeling the Immune Landscape: How Obesity-Induced SASPs Create a Pro-Tumorigenic Niche.Current obesity reports · 2026Review
- Association of Body Mass Index with Tumor-Infiltrating Lymphocytes and Treatment Response in Early HER2-Positive Breast Cancer.International journal of women's health · 2026Article
- VEGF-Leptin Crosstalk in Breast and Ovarian Cancer: Drivers of Angiogenesis and Progression.Cancer management and research · 2026Review
- Obesity, white adipose tissue and cancer.The FEBS journal · 2025Review
- Correlations between biological markers of the perirenal adipose tissue and clinical features of patients with localized kidney cancer.Frontiers in medicine · 2025Article
- A preliminary mechanistic exploration of the effect of leptin on the docetaxel sensitivity of MDA‑MB‑231 triple‑negative breast cancer cells.Molecular and clinical oncology · 2024Article
- Role of Leptin and Adiponectin in Carcinogenesis.Cancers · 2023Review
- Leptin: A Heavyweight Player in Obesity-Related Cancers.Biomolecules · 2023Review
- Obesity and cancer: focus on leptin.Molecular biology reports · 2023Review
- Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advancedTranslational lung cancer research · 2023Article
- The Adipocyte-Macrophage Relationship in Cancer: A Potential Target for Antioxidant Therapy.Antioxidants (Basel, Switzerland) · 2023Review
- Breast cancer microenvironment and obesity: challenges for therapy.Cancer metastasis reviews · 2022Review
- The clinical relevance of unfolded protein response signaling in breast cancer.American journal of cancer research · 2022Article
- Review
- Leptin Protein Expression and Promoter Methylation in Ovarian Cancer: A Strong Prognostic Value with Theranostic Promises.International journal of molecular sciences · 2021Article
- Progranulin: A proangiogenic factor in visceral adipose tissue in tumoral and non-tumoral visceral pathology.Experimental and therapeutic medicine · 2021Article
- Obesity and altered angiogenic-related gene expression in endometrial cancer.Gynecologic oncology · 2021Article
- Role of Notch, IL-1 and leptin expression in colorectal cancer.Experimental and therapeutic medicine · 2021Article
- Enhanced Thermogenesis in Triple-Negative Breast Cancer Is Associated with Pro-Tumor Immune Microenvironment.Cancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Obesity is linked to increased incidence of breast cancer. The precise causes and mechanisms of these morbid relationships are unknown. Contradictory data on leptin angiogenic actions have been published. However, accumulating evidence would suggest that leptin's pro-angiogenic effects in cancer play an essential role in the disease. Leptin, the main adipokine secreted by adipose tissue, is also abnormally expressed together with its receptor (OB-R) by breast cancer cells. Leptin induces proliferation and angiogenic differentiation of endothelial cells upregulates VEGF/VEGFR2 and transactivates VEGFR2 independent of VEGF. Leptin induces two angiogenic factors: IL-1 and Notch that can increase VEGF expression. Additionally, leptin induces the secretion and synthesis of proteases and adhesion molecules needed for the development of angiogenesis. Leptin's paracrine actions can further affect stromal cells and tumor associated macrophages, which express OB-R and secrete VEGF and IL-1, respectively. A complex crosstalk between leptin, Notch and IL-1 (NILCO) that induces VEGF/VEGFR2 is found in breast cancer. Leptin actions in tumor angiogenesis could amplify, be redundant and/or compensatory to VEGF signaling. Current failure of breast cancer anti-angiogenic therapies emphasizes the necessity of targeting the contribution of other pro-angiogenic factors in breast cancer. Leptin's impact on tumor angiogenesis could be a novel target for breast cancer, especially in obese patients. However, more research is needed to establish the importance of leptin in tumor angiogenesis. This review is focused on updated information on how leptin could contribute to tumor angiogenesis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.